AVROBIO to End Gaucher Disease Trials, Explore Sale
AVROBIO, a promising developer of clinical-stage gene therapy solutions, has announced... Read more
AVROBIO, a promising developer of clinical-stage gene therapy solutions, has announced... Read more
Study results demonstrate first small molecule approach to significantly reduce... Read more
NORD provides new designation to medical centers to define standards... Read more
GT-02287and GT-02329 compounds display positive effects on GCase activity and... Read more
U.S. Food and Drug Administration granted Fast Track Designation to... Read more
Activity of GBA and GALC Enzymes Play Key Roles in... Read more
A Five-year Commitment From Takeda Will Help Children’s National Launch... Read more
AVROBIO announced that the U.S. Food and Drug Administration (FDA)... Read more
U.S. Food and Drug Administration (FDA) has accepted Prevail’s Investigational... Read more
The NGF is profoundly saddened by the recent passing of... Read more
Living a Better Today